ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

  • Abstract Number: 0033 • ACR Convergence 2025

    Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity

    Lauren Vanderlinden1, Jun Inamo2, Jennifer Seifert3, V. Michael Holers4, Joel Guthridge5, Kevin Deane6 and Fan Zhang7, 1University of Colorado Anschutz Medical Campus, Monument, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 4University of Colorado, Denver, CO, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 7The University of Colorado, Aurora, CO

    Background/Purpose: Human leukocyte antigen (HLA) class II genes play a central role in antigen presentation and immune modulation. The shared epitope (SE) region within HLA-DRB1…
  • Abstract Number: 2250 • ACR Convergence 2025

    Clinical and Serological Predictors of Interstitial Lung Disease in Rheumatoid Arthritis: Are Anti-Citrullinated Protein Antibodies Truly Relevant?

    Martí Aguilar-Coll1, Javier Narváez2, Montserrat Roig Kim1, Laia De Daniel Bisbe1, Pol Maymó-Paituvi1, Judith Palacios-Olid1 and Joan Miquel Nolla1, 1Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: Evidence on which risk factors predict the development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) is scarce and of low…
  • Abstract Number: 2248 • ACR Convergence 2025

    Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study

    Margaret Ma1, Khai Pang Leong2, ee tzun koh2, Preeti Dhanasekaran3, janique peyper4, bermet abylova4, Anselm Mak3 and Peter Cheung1, 1National University Hospital, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Standard BioTools, Singapore, Singapore

    Background/Purpose: Autoantibody-based biomarkers including ACPA and RF are of established clinical use in rheumatoid arthritis (RA) and are ingrained in international classification criteria. However, other…
  • Abstract Number: 1701 • ACR Convergence 2025

    Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen

    Vibha Jha1, Brian Freed2, Niyun Jin1, Manjula Miglani1 and Christina Roark2, 1University of Colorado, Aurora, CO, 2Clinimmune Labs Immunology, School of Medicine, Aurora, CO

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease with a strong genetic association to Class II HLA-DRB1*04:01. Presentation of arthritogenic peptides bound to DRB1*04:01…
  • Abstract Number: 1678 • ACR Convergence 2025

    Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study

    Andrew Cope1, Joana Vasconcelos1, Marianna Jasenecova2, Andrew Filer3, Karim Raza4, Sumera Qureshi1, Maria Antonietta D'Agostino5, Iain McInnes6, Stefan Siebert6, John Isaacs7, Arthur Pratt8, Benjamin A. Fisher9, Christopher Buckley10, Paul Emery11, Kulveer Mankia11, Pauline Ho12, MAYA BUCH13, Coziana Ciurtin14, Dirkjan van Schaardenburg15, Tom Huizinga16, René Toes16, Caroline Murphy1 and A. Toby Prevost1, 1King's College London, London, United Kingdom, 2King's College London, London, 3The University of Birmingham, Birmingham, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 6University of Glasgow, Glasgow, United Kingdom, 7Newcastle University, Newcastle upon Tyne, United Kingdom, 8University of Newcastle, Newcastle, United Kingdom, 9King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, 10University of Oxford, Oxford, United Kingdom, 11University of Leeds, Leeds, England, United Kingdom, 12The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom, 13UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, 14University College London, London, 15Amsterdam UMC, Amsterdam, Netherlands, 16Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Clinical trials aimed at delaying or preventing rheumatoid arthritis (RA) in individuals at risk have been published with variable results. In the APIPPRA study,…
  • Abstract Number: 0914 • ACR Convergence 2025

    Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals

    Xiaohao Wu1, Mengrui Zhang2, Orr Sharpe3, V. Michael Holers4, Jane Buckner5, Gary Firestein5, Eddie James6, Kevin Deane7 and William H. Robinson8, 1Stanford Uniersity, Stanford, 2Stanford University, Stanford, CA, 3Stanford University, Stanford, 4University of Colorado Anschutz Medical Campus, Aurora, 5Benaroya Research Institute, Seattle, 6Benaroya Research Institute, Benaroya Research Institute, 7University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 8Stanford University, Palo Alto, CA

    Background/Purpose: The cellular and molecular mechanisms underlying the progression from anti-citrullinated protein antibody (ACPA) positivity to clinical rheumatoid arthritis (RA) remain poorly understood. Defining these…
  • Abstract Number: 0833 • ACR Convergence 2025

    Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA

    Timothy Wilson1, Claudia Lugo2, Marie Feser3, Mark Gillespie4, Troy Torgerson5, Gary Firestein6, V. Michael Holers7, Kevin Deane8 and Kristen Demoruelle9, 1Thomas Jefferson University, Philadelphia, PA, 2University of Colorado, Denver, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4Allen Institute for Immunology, Seattle, WA, 5Allen Institute for Immunology, Enumclaw, WA, 6University of California, San Diego, San Diego, CA, 7University of Colorado Anschutz Medical Campus, Aurora, 8University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 9University of Colorado Anschutz Medical Campus, Golden, CO

    Background/Purpose: The presence of serum anti-CCP-IgG antibodies can predict the future development of clinically evident RA. Neutrophil extracellular trap (NET) formation can be a source…
  • Abstract Number: 0799 • ACR Convergence 2025

    Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis

    Mario Navarrete Lagos, Ramiza Zaman, Jun Kim, Jeba Atkia Maisha, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: In Rheumatoid Arthritis (RA), autoantibodies develop against endogenous proteins containing the amino acid citrulline, which results from a post-translational modification of arginine catalyzed by…
  • Abstract Number: 0471 • ACR Convergence 2025

    An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial

    Fredrik Albach1, Ioanna Minopoulou1, Artur Wilhelm2, Robert Biesen1, Arnd Kleyer1, Norman Drzeniek3, Edgar Wiebe4, Anja Fleischmann3, Dominic Borie5, Vincent Casteleyn3, Tobias Alexander3, Christian Furth6, Jan Zernicke3, Burkhard Muche7, Sandra Hermann4, Pfeil Alexander8, Veronika Scholz3, Elpida Phithak3, Olaf Penack9, Kamran Movassaghi9, Eva Vanessa Schrezenmeier10, Udo Schneider3, Antonia Busse11, Georg Schett12, Ulrich Keller11, Lars Bullinger9, Gerhard Krönke13, Marie Luise Hütter-Krönke14 and David Simon15, 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, 3Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, 4Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, 5Kyverna Therapeutics, Emeryville, CA, 6Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, 7Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 8Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, 9Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, 10Department of Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, 11Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; German Cancer Consortium (DKTK) partner site Charité Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany, Berlin, 12Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 13Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, 14Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany, Berlin, 15Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by autoreactive B cells that produce anti-citrullinated protein antibodies (ACPA), contributing to sustained synovial inflammation…
  • Abstract Number: 0078 • ACR Convergence 2025

    Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis

    Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA

    Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
  • Abstract Number: 0073 • ACR Convergence 2025

    HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis

    S. Janna Bashar1, Courtney Myhr1, Adam Titi1, Zihao Zheng1 and Miriam Shelef2, 1University of Wisconsin-Madison, Madison, 2University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross-reactive binding to many antigens containing short motifs, or more private with…
  • Abstract Number: 1648 • ACR Convergence 2024

    In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells

    Giulia Frazzei1, Ana Merino Vico2, Jan Piet van Hamburg2, Ronald Van Vollenhoven3 and Sander Tas4, 1Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 4Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis and are associated with disease severity. Detailed analysis of ACPApos B cells…
  • Abstract Number: 1679 • ACR Convergence 2024

    Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study

    Nathanial Eddy1, Jane Buckner2, Paul Emery3, Michael Weinblatt4, Vivian Bykerk5, Andrew Cope6, Gerd Burmester7, Yoshiya Tanaka8, Gustavo Citera9, Peter Nash10, Quentin Dornic11, Peter Schafer12, Sheila Kelly13, Michael Maldonado11 and Jinqi Liu11, 1Bristol Myers Squibb, Princeton, 2Benaroya Research Institute, Seattle, WA, 3University of Leeds, Leeds, United Kingdom, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Hospital For Special Surgery, New York, NY, 6King's College London, London, United Kingdom, 7Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 8Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 9Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 10Griffith University, Brisbane, Australia, 11Bristol Myers Squibb, Princeton, NJ, 12Bristol Myers Squibb, BELLE MEAD, NJ, 13Bristol Myers Squibb, Doylestown, PA

    Background/Purpose: Despite considerable advances in pharmacologic approaches to RA management, a better understanding of the underlying immunopathology is still needed.1,2 A dysregulated immune system is…
  • Abstract Number: 0039 • ACR Convergence 2024

    Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients’ Serum

    Lacie Scaletta1, Teneema Kuriakose1, Sambit Nanda1, Mia Collins2, Erika Darrah3, Iain McInnes4, David Close5 and Gary Sims1, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 3Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 4University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 5Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) promote inflammation and joint tissue injury and define a poor prognostic group of patients with rheumatoid arthritis (RA). Citrullinated autoantigens…
  • Abstract Number: 1871 • ACR Convergence 2024

    A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population

    Tada Vargas1, Lauren Vanderlinden2, Patrick Carry3, Kristen Demoruelle4, Marie Feser1, Katerina Kechris5, Jane Buckner6, William Robinson7, Gary Firestein8, Michael Holers1, Kevin Deane9 and Jill Norris10, 1Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2Colorado School of Public Health, Monument, CO, 3Department of Orthopedics, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Golden, CO, 5Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, 6Benaroya Research Institute, Seattle, WA, 7Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA, 8University of California, San Diego, San Diego, CA, 9University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 10Colorado School of Public Health, Denver, CO

    Background/Purpose: Serum autoantibodies, such as ACPA and RF, are commonly detectable prior to the development of seropositive clinical RA; however, not all individuals with these…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology